Clinical Trial Update: Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer [Phase 1]

View source ↗

Summary

An early-phase Phase 1 study evaluating antibody CC-1 in men with biochemical recurrence of prostate cancer. The study is sponsored by University Hospital Tuebi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CC-1 (PSMAxCD3 bispecific antibody)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Prostate Cancer Recurrent | Phase 1 | Status: RECRUITING